A gene-editing company which has a therapy in Phase I clinical trials that is designed to prevent atherosclerosis and therein reshape the nature of human health. Atherosclerosis is the underlying cause of 50% of deaths in western nations and is the dominant cause of cardiovascular disease, the leading cause of death in the world. Atherosclerosis refers to the process in which apoB lipoproteins produced by the liver and circulating in the blood penetrate the lining of blood vessels and are retained beneath the lining, triggering immune cells to respond and plaque to form. The atherosclerotic plaque narrows the blood vessels and can create the clots which result in heart attack and stroke. This process begins early in life for almost all human beings.